Comorbidity burden, healthcare resource utilization, and costs in chronic gout patients refractory to conventional urate-lowering therapy

American Journal of Therapeutics

Volumn 19, Issue 6, 2012, Pages

  Wu, Eric Q ^a   Forsythe, Anna ^b   Guérin, Annie ^a,c   Yu, Andrew P ^a   Latremouille Viau, Dominick ^a   Tsaneva, Magda ^a  

^a ANALYSIS GROUP   (United States)

^b Savient Pharmaceuticals Inc   (United States)

^c INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

Author keywords

economic burden; flares; Gout; healthcare costs; healthcare resource use

Indexed keywords

ALLOPURINOL;

ADULT; ARTICLE; COHORT ANALYSIS; COMORBIDITY; COMPARATIVE STUDY; CONTROLLED STUDY; DATA BASE; EMERGENCY WARD; FEMALE; GOUT; HEALTH CARE COST; HEALTH CARE UTILIZATION; HOSPITALIZATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; OUTPATIENT CARE; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT RESPONSE;

ADULT; ALLOPURINOL; CASE-CONTROL STUDIES; CHRONIC DISEASE; COHORT STUDIES; COMORBIDITY; COST OF ILLNESS; DATABASES, FACTUAL; EMERGENCY SERVICE, HOSPITAL; FEMALE; GOUT; GOUT SUPPRESSANTS; HEALTH CARE COSTS; HEALTH SERVICES; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; PREVALENCE; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES;

EID: 84870250393     PISSN: 10752765     EISSN: 15363686     Source Type: Journal    
DOI: 10.1097/MJT.0b013e31820543c5     Document Type: Article

References (27)

1. Arthritis Foundation Web site. Disease Center: Gout. http://www. arthritis.org/disease-center.php?disease-id=42. Accessed April 13, 2010.
2. Kim KY, Schumacher RH, Hunsche E, et al. A literature review of the epidemiology and treatment of acute gout. Clin Ther. 2003;25:1593-1617. (Pubitemid 36805619)
3. Mikuls TR, Farrar JT, Bilker WB, et al. Gout epidemiology: results from the UK General Practice Research Database, 1990-1999. Ann Rheum Dis. 2005;64:267-272. (Pubitemid 40197509)
4. Annemans L, Spaepen E, Gaskin M, et al. Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000-2005. Ann Rheum Dis. 2008; 67:960-966. (Pubitemid 351956658)
5. Weaver AL. Epidemiology of gout. Cleve Clin J Med. 2008; 75(Suppl 5):S9-S12.
6. Schlesinger N, Schumacher HR. Gout: can management be improved? Curr Opin Rheumatol. 2001;13:240-244. (Pubitemid 32430079)
7. Wu EQ, Patel PA,Mody RR, et al. Frequency, risk, and cost of gout-related episodes among the elderly: does serum uric acid level matter. J Rheumatol. 2009;36:1032-1040.
8. Shoji A, Yamanaka H, Kamatani N. A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis Rheum. 2004;51:321-325. (Pubitemid 38725128)
9. Sarawate CA, Patel PA, Schumacher HR, et al. Serum urate levels and gout flares: analysis from managed care data. J Clin Rheumatol. 2006;12:61-65. (Pubitemid 44309598)
10. Emmerson BT. The management of gout. N Engl J Med. 1996;334:445-451. (Pubitemid 126528536)
11. Fels E, Sundy JS. Refractory gout: what is it and what to do about it? Curr Opin Rheumatol. 2008;20:198-202. (Pubitemid 351339893)
12. Edwards NL. Treatment-failure gout: a moving target. Arthritis Rheum. 2008;58:2587-2590.
13. Arellano F, Sacristán JA. Allopurinol hypersensitivity syndrome: a review. Ann Pharmacother. 1993;27:337-343. (Pubitemid 23086961)
14. Singer JZ, Wallace SL. The allopurinol hypersensitivity syndrome. Unnecessary morbidity and mortality. Arthritis Rheum. 1986;29:82-87. (Pubitemid 17015410)
15. Rosenthal AK, Ryan LM. Treatment of refractory crystalassociated arthritis. Rheum Dis Clin North Am. 1995;21: 151-161.
16. Perez-Ruiz F, Alonso-Ruiz A, Calabozo M, et al. Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout. Ann Rheum Dis. 1998;57:545-549. (Pubitemid 28474062)
17. Becker MA, Schumacher HR Jr, Wortmann RL, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout.NEngl JMed. 2005;353:2450-2461. (Pubitemid 41781828)
18. Becker, MA, Schumacher HR, MacDonald PA, et al. efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout. J Rheumatol. 2009;36:1273-1282
19. Halpern R, FuldeoreMJ, Mody RR, et al. The effect of serum urate on gout flares and their associated costs: an administrative claims analysis. J Clin Rheumatol. 2009;15:3-7.
20. Wu EQ, Patel PA, Yu AP, et al. Disease-related and allcause healthcare costs of elderly patients with gout. J Manag Care Pharm. 2008;14:164-175. (Pubitemid 351453817)
21. Brook RA, Kleinman NL, Patel PA, et al. The economic burden of gout on an employed population. Curr Med Res Opin. 2006;22:1381-1389. (Pubitemid 44085590)
22. Charlson, ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40: 373-383. (Pubitemid 17055592)
23. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45:613-619.
24. Singh JA, Strand V. Gout is associated with more comorbidities, poorer health-related quality of life and higher healthcare utilisation in US veterans. Ann Rheum Dis. 2008;67:1310-1316.
25. Becker MA, Schumacher HR, Benjamin KL, et al. Quality of life and disability in patients with treatment-failure gout. J Rheumatol. 2009;36:1041-1048.
26. Gutman AB. The past four decades of progress in the knowledge of gout, with an assessment of the present status. Arthritis Rheum. 1973;16:431-445.
27. Brixner DI, Ho MJ. Clinical, humanistic, and economic outcomes of gout. Am J Manag Care. 2005;15(Suppl l): S459-S464. (Pubitemid 41720938)